Retrieve available abstracts of 66 articles: HTML format
Single Articles
June 2025
DE GROOT AF, Cohen D, Heijns JB, Mandigers CMPW, et al Ribociclib-letrozole combination as an alternative for neoadjuvant chemotherapy
in selected post-menopausal patients with luminal breast cancer (BOOG 2017-01).
Clin Cancer Res. 2025 Jun 10. doi: 10.1158/1078-0432.CCR-24-3402. PubMedAbstract available
May 2025
PRIEDIGKEIT N, Harrison B, Shue R, Hughes ME, et al Clinicogenomic characterization of inflammatory breast cancer.
Clin Cancer Res. 2025 May 16. doi: 10.1158/1078-0432.CCR-24-2081. PubMedAbstract available
LI Y, Zhang T, Korkaya H, Liu S, et al Correction: Sulforaphane, a Dietary Component of Broccoli/Broccoli Sprouts,
Inhibits Breast Cancer Stem Cells.
Clin Cancer Res. 2025;31:2062. PubMed
GWIN WR 3RD, Hurvitz SA TOP1 Priority: Advancing Biomarker-Driven Patient Selection for the Use of ADCs.
Clin Cancer Res. 2025;31:1824-1826. PubMedAbstract available
CHUMSRI S, Larson JJ, Liu E, Tenner KS, et al Pembrolizumab in Combination with Binimetinib in Patients with Unresectable
Locally Advanced or Metastatic Triple-Negative Breast Cancer.
Clin Cancer Res. 2025;31:1885-1893. PubMedAbstract available
FASCHING PA, Schmatloch S, Hauke J, Rey J, et al Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in
Patients with HER2-Negative Breast Cancer and HRD-Long-term Survival of the
GeparOLA Study.
Clin Cancer Res. 2025;31:1596-1604. PubMedAbstract available
April 2025
CLARK AS, Zhao F, Klein P, Montero AJ, et al A Phase II Randomized Study of Paclitaxel alone or combined with Pelareorep with
or without Avelumab in Metastatic Hormone Receptor Positive Breast Cancer: the
BRACELET-01/PrE0113 study.
Clin Cancer Res. 2025 Apr 29. doi: 10.1158/1078-0432.CCR-24-2701. PubMedAbstract available
JOHANSSON H, Macis D, Oliva M, Puntoni M, et al Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast
Cancer in the Phase III Tam-01 Trial.
Clin Cancer Res. 2025 Apr 28:OF1-OF6. doi: 10.1158/1078-0432.CCR-24-2987. PubMedAbstract available
JIAO D, Qiao J, Sun X, Wang C, et al Application of Neoadjuvant Docetaxel Plus Cisplatin in Early-Stage
Triple-Negative Breast Cancer (HELEN-001): Results from a Phase II Trial.
Clin Cancer Res. 2025 Apr 21. doi: 10.1158/1078-0432.CCR-25-0289. PubMedAbstract available
YAP TA, Goldman JW, Vinayak S, Tomova A, et al First-In-Human Phase 1/2a Study of the First-In-Class CDK2/4/6 Inhibitor
PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer.
Clin Cancer Res. 2025 Apr 17. doi: 10.1158/1078-0432.CCR-24-2740. PubMedAbstract available
GOUGH M, Kwah KKX, Khan T, Ghosh S, et al Receptor CDCP1 Is a Potential Target for Personalized Imaging and Treatment of
Poor Outcome HER2+, Triple-Negative, and Metastatic ER+/HER2- Breast Cancers.
Clin Cancer Res. 2025;31:1504-1519. PubMedAbstract available
JONES LW, Lavery JA, Tsai BL, Moskowitz CS, et al A Co-Clinical Trial of Exercise Therapy in Breast Cancer Prevention.
Clin Cancer Res. 2025 Apr 4. doi: 10.1158/1078-0432.CCR-24-4298. PubMedAbstract available
LIU J, Song C, Yang Y, Wang X, et al Safety and Efficacy of KN046 in combination with KN026 in Patients with advanced
HER2-positive Breast Cancer: a Phase II Trial.
Clin Cancer Res. 2025 Apr 4. doi: 10.1158/1078-0432.CCR-24-3888. PubMedAbstract available
March 2025
JILDERDA MF, Zhang Y, Rebattu V, Salunga R, et al Identification of Early-Stage Breast Cancer with Minimal Risk of Recurrence by
Breast Cancer Index.
Clin Cancer Res. 2025 Mar 27. doi: 10.1158/1078-0432.CCR-24-3836. PubMedAbstract available
ADEMUYIWA FO, Ma CX, Weilbaecher K, Suresh R, et al Detection of circulating tumor DNA using a tissue-free epigenomic assay is a
highly prognostic biomarker in early-stage triple negative breast cancer.
Clin Cancer Res. 2025 Mar 21. doi: 10.1158/1078-0432.CCR-24-3145. PubMedAbstract available
JANNI W, Friedl TWP, Yab TC, Bidard FC, et al Clinical validity of repeated circulating tumor cell enumeration as an early
treatment monitoring tool for metastatic breast cancer in the PREDICT global
pooled analysis.
Clin Cancer Res. 2025 Mar 18. doi: 10.1158/1078-0432.CCR-24-3108. PubMedAbstract available
February 2025
FASCHING PA, Slamon D, Nowecki Z, Kukielka-Budny B, et al Health-related quality of life in patients with HR+/HER2- early breast cancer
treated with ribociclib plus a nonsteroidal aromatase inhibitor: results from the
NATALEE trial.
Clin Cancer Res. 2025 Feb 28. doi: 10.1158/1078-0432.CCR-24-1724. PubMedAbstract available
LIN CA, Chica-Parrado MR, Unni N, Jaeger E, et al ESR1 Y537S and D538G mutations drive resistance to CDK4/6 inhibitors in estrogen
receptor-positive breast cancer.
Clin Cancer Res. 2025 Feb 25. doi: 10.1158/1078-0432.CCR-24-2307. PubMedAbstract available
POUGOUE KETCHEMEN J, Njotu FN, Babeker H, Monzer A, et al Complete Remissions of HER2-Positive Trastuzumab-Resistant Xenografts Using a
Potent [225Ac]Ac-Labeled Anti-HER2 Antibody-Drug Radioconjugate.
Clin Cancer Res. 2025;31:685-696. PubMedAbstract available
GOEL S, Jovanovic B, Chu X, Hughes M, et al A phase II study of abemaciclib for patients with retinoblastoma-positive,
triple-negative metastatic breast cancer.
Clin Cancer Res. 2025 Feb 5. doi: 10.1158/1078-0432.CCR-24-2647. PubMedAbstract available
DRAKE RJG, Landen AH, Holmberg E, Stenmark Tullberg A, et al Endothelial cell pY397-FAK expression predicts risk of breast cancer recurrences
after radiotherapy in SweBCG91-RT cohort.
Clin Cancer Res. 2025 Feb 5. doi: 10.1158/1078-0432.CCR-24-2939. PubMedAbstract available
KOBOLD S RORing CAR T Cells in Solid and Hematologic Cancers: Same but Different.
Clin Cancer Res. 2025;31:437-438. PubMedAbstract available
JAEGER-RUCKSTUHL CA, Specht JM, Voutsinas JM, MacMillan HR, et al Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and
Epithelial Malignancies.
Clin Cancer Res. 2025;31:503-514. PubMedAbstract available
January 2025
SOOD R, Niemierko A, Ryan L, Spring L, et al Impact of Race/Ethnicity on Clinical and Genomic Characteristics, Trial
Participation, and Genotype-Matched Therapy among Patients with Metastatic Breast
Cancer.
Clin Cancer Res. 2025 Jan 27. doi: 10.1158/1078-0432.CCR-24-2825. PubMedAbstract available
GOUDA MA, Gonugunta A, Dumbrava EE, Yap TA, et al Human Epidermal Growth Factor Receptor 2 Loss Following Treatment with
Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer.
Clin Cancer Res. 2025 Jan 22. doi: 10.1158/1078-0432.CCR-24-3468. PubMedAbstract available
RIOS-HOYO A, Xiong K, Dai J, Yau C, et al Hormone Receptor-Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely
Resemble Triple-Negative Breast Cancers.
Clin Cancer Res. 2025;31:403-413. PubMedAbstract available
VIDAL M, Falato C, Pascual T, Sanchez-Bayona R, et al Elacestrant in women with estrogen receptor-positive and HER2-negative early
breast cancer: results from the preoperative window-of-opportunity ELIPSE trial.
Clin Cancer Res. 2025 Jan 16. doi: 10.1158/1078-0432.CCR-24-2460. PubMedAbstract available
ELLIOTT MJ, Howarth K, Main S, Fuentes Antras J, et al Ultrasensitive Detection and Monitoring of Circulating Tumor DNA using Structural
Variants in Early-Stage Breast Cancer.
Clin Cancer Res. 2025 Jan 9. doi: 10.1158/1078-0432.CCR-24-3472. PubMedAbstract available
MAURYA SK, Jaramillo-Gomez JA, Rehman AU, Gautam SK, et al Mucin5AC promotes breast cancer brain metastasis through cMET/CD44v6.
Clin Cancer Res. 2025 Jan 6. doi: 10.1158/1078-0432.CCR-24-1977. PubMedAbstract available
HUANG H, Couch RE, Karam R, Hu C, et al Pathogenic Variants in Cancer Susceptibility Genes Predispose to Ductal Carcinoma
In Situ of the Breast.
Clin Cancer Res. 2025;31:130-138. PubMedAbstract available
ABELMAN RO, Wu B, Barnes H, Medford A, et al TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with
Metastatic Breast Cancer.
Clin Cancer Res. 2025 Jan 2. doi: 10.1158/1078-0432.CCR-24-2771. PubMedAbstract available
December 2024
VILLACAMPA G, Llop-Guevara A, Filmann N, Herencia A, et al RAD51 testing in patients with early HER2-negative breast cancer and homologous
recombination deficiency: post-hoc analysis of the GeparOla trial.
Clin Cancer Res. 2024 Dec 30. doi: 10.1158/1078-0432.CCR-24-3148. PubMedAbstract available
HAMILTON E, Galsky MD, Ochsenreither S, Del Conte G, et al Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or
Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study.
Clin Cancer Res. 2024;30:5548-5558. PubMedAbstract available
November 2024
MERIC-BERNSTAM F, Yuca E, Evans KW, Zhao M, et al Anti-tumor activity and biomarker analysis for TROP2-antibody drug conjugate
Datopotamab deruxtecan in patient-derived breast cancer xenograft models.
Clin Cancer Res. 2024 Nov 25. doi: 10.1158/1078-0432.CCR-24-1948. PubMedAbstract available
FERRARIO C, Mackey J, Gelmon KA, Levasseur N, et al Phase Ib pharmacodynamic study of the MNK inhibitor Tomivosertib (eFT508)
combined with paclitaxel in patients with refractory metastatic breast cancer.
Clin Cancer Res. 2024 Nov 22. doi: 10.1158/1078-0432.CCR-24-0841. PubMedAbstract available
ANAMPA JD, Flynn DL, Leary C, Oh S, et al Phase Ib clinical and pharmacodynamic study of the TIE2 kinase inhibitor
rebastinib with paclitaxel or eribulin in HER2-negative metastatic breast cancer.
Clin Cancer Res. 2024 Nov 12. doi: 10.1158/1078-0432.CCR-24-2464. PubMedAbstract available
October 2024
REDITI M, Fimereli D, Mileva M, Wimana Z, et al Integrating molecular imaging and transcriptomic profiling in advanced
HER2-positive breast cancer receiving trastuzumab emtansine (T-DM1): an analysis
of the ZEPHIR clinical trial.
Clin Cancer Res. 2024 Oct 29. doi: 10.1158/1078-0432.CCR-24-1007. PubMedAbstract available
NEVEN P, Stahl N, Vidal M, Martin M, et al A preoperative window-of-opportunity study of oral SERD, imlunestrant, in newly
diagnosed ER-positive, HER2-negative early breast cancer: Results from EMBER-2
Study.
Clin Cancer Res. 2024 Oct 8. doi: 10.1158/1078-0432.CCR-24-2113. PubMedAbstract available
BARDIA A, Cortes J, Bidard FC, Neven P, et al Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors:
Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine
Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups.
Clin Cancer Res. 2024;30:4299-4309. PubMedAbstract available
September 2024
DUGO M, Huang CS, Egle D, Bermejo B, et al The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant
Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer.
Clin Cancer Res. 2024 Sep 23:OF1-OF10. doi: 10.1158/1078-0432.CCR-24-0149. PubMedAbstract available
QUINTELA-FANDINO M, Bermejo B, Zamora E, Moreno F, et al High mechanical conditioning by tumor extracellular matrix stiffness is a
predictive biomarker for anti-fibrotic therapy in HER2-negative breast cancer.
Clin Cancer Res. 2024 Sep 16. doi: 10.1158/1078-0432.CCR-24-1518. PubMedAbstract available
GIORDANO A, Kumthekar PU, Jin Q, Binboga Kurt B, et al A phase II study of atezolizumab, pertuzumab, and high-dose trastuzumab for
central nervous system metastases in patients with HER2-positive breast cancer.
Clin Cancer Res. 2024 Sep 3. doi: 10.1158/1078-0432.CCR-24-1161. PubMedAbstract available
August 2024
ROJO F, Najera L, Lirola J, Jimenez J, et al Editor's Note: 4E-Binding Protein 1, a Cell Signaling Hallmark in Breast Cancer
That Correlates with Pathologic Grade and Prognosis.
Clin Cancer Res. 2024;30:3641. PubMed
GILLMORE R, Xue SA, Holler A, Kaeda J, et al Editor's Note: Detection of Wilms' Tumor Antigen-Specific CTL in Tumor-Draining
Lymph Nodes of Patients with Early Breast Cancer.
Clin Cancer Res. 2024;30:3642. PubMed
JOVANOVIC B, Church SE, Gorman KM, North K, et al Integrative multi-omic profiling of triple-negative breast cancer for identifying
suitable therapies.
Clin Cancer Res. 2024 Aug 13. doi: 10.1158/1078-0432.CCR-23-1242. PubMedAbstract available
PIFFOUX M, Jacquemin J, Petera M, Durand S, et al Metabolomic prediction of breast cancer treatment induced neurological and
metabolic toxicities.
Clin Cancer Res. 2024 Aug 6. doi: 10.1158/1078-0432.CCR-24-0195. PubMedAbstract available
July 2024
DENT RA, Kim SB, Oliveira M, Barrios C, et al Ipatasertib plus Paclitaxel for patients with PIK3CA/AKT1/PTEN-Altered Locally
Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the
IPATunity130 Phase III Trial.
Clin Cancer Res. 2024 Jul 26. doi: 10.1158/1078-0432.CCR-24-0465. PubMedAbstract available
SUN X, Kennedy LC, Gonzalez-Ericsson PI, Sanchez V, et al Associations of immune checkpoint predictive biomarkers MHC-I and MHC-II with
clinical and molecular features in a diverse breast cancer cohort.
Clin Cancer Res. 2024 Jul 15. doi: 10.1158/1078-0432.CCR-24-1286. PubMedAbstract available
LLOMBART-CUSSAC A, Perez-Garcia J, Braso-Maristany F, Pare L, et al HER2DX Genomic Assay in HER2-positive Early Breast Cancer Treated with
Trastuzumab and Pertuzumab: A Correlative Analysis from PHERGain Phase II Trial.
Clin Cancer Res. 2024 Jul 12. doi: 10.1158/1078-0432.CCR-24-0464. PubMedAbstract available
STEARNS V, Jegede OA, Chang VT, Skaar TC, et al A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor
Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11.
Clin Cancer Res. 2024;30:2709-2718. PubMedAbstract available
June 2024
SCHMIESTER L, Braso-Maristany F, Gonzalez-Farre B, Pascual T, et al Computational model predicts patient outcomes in Luminal B breast cancer treated
with endocrine therapy and CDK4/6 inhibition.
Clin Cancer Res. 2024 Jun 26. doi: 10.1158/1078-0432.CCR-24-0244. PubMedAbstract available
JANK P, Karn T, van Mackelenbergh M, Lindner J, et al An analysis of PIK3CA hotspot mutations and response to neoadjuvant therapy in
breast cancer patients from four prospective clinical trials.
Clin Cancer Res. 2024 Jun 5. doi: 10.1158/1078-0432.CCR-24-0459. PubMedAbstract available
ZHANG Q, Cai Z, Gerratana L, Davis AA, et al Early evaluation of risk stratification and clinical outcomes for patients with
advanced breast cancer through combined monitoring of baseline circulating tumor
cells and DNA.
Clin Cancer Res. 2024 Jun 3. doi: 10.1158/1078-0432.CCR-24-0535. PubMedAbstract available
MAKHLIN I, Demissei BG, D'Agostino R, Hundley WG, et al Statins Do Not Significantly Affect Oxidative Nitrosative Stress Biomarkers in
the PREVENT Randomized Clinical Trial.
Clin Cancer Res. 2024;30:2370-2376. PubMedAbstract available
May 2024
GOUGH SM, Flanagan JJ, Teh J, Andreoli M, et al Oral estrogen receptor PROTAC(R) vepdegestrant (ARV-471) is highly efficacious as
monotherapy and in combination with CDK4/6 or PI3K/mTOR pathway inhibitors in
preclinical ER+ breast cancer models.
Clin Cancer Res. 2024 May 31. doi: 10.1158/1078-0432.CCR-23-3465. PubMedAbstract available
CHEUNG A, Chenoweth AM, Johansson A, Laddach R, et al Anti-EGFR antibody-drug conjugate carrying an inhibitor targeting CDK restricts
triple-negative breast cancer growth.
Clin Cancer Res. 2024 May 21. doi: 10.1158/1078-0432.CCR-23-3110. PubMedAbstract available
HADDAD TC, Suman VJ, Giridhar KV, Sideras K, et al Anastrozole dose escalation for optimal estrogen suppression in postmenopausal
early-stage breast cancer: A prospective trial.
Clin Cancer Res. 2024 May 16. doi: 10.1158/1078-0432.CCR-24-0341. PubMedAbstract available
WANDER SA, Bardia A Cracking the Genomic Code of CDK4/6 Inhibitor Resistance.
Clin Cancer Res. 2024;30:2008-2010. PubMedAbstract available
BARDIA A, Sun S, Thimmiah N, Coates JT, et al Antibody Drug Conjugate Sacituzumab Govitecan Enables A Sequential TOP1/PARP
Inhibitor Cancer Therapy Strategy in Breast Cancer Patients.
Clin Cancer Res. 2024 May 6. doi: 10.1158/1078-0432.CCR-24-0428. PubMedAbstract available
April 2024
BOTTOSSO M, Miglietta F, Vernaci GM, Giarratano T, et al Gene-expression assays to tailor adjuvant endocrine therapy for HR+/HER2- breast
cancer.
Clin Cancer Res. 2024 Apr 24. doi: 10.1158/1078-0432.CCR-23-4020. PubMedAbstract available
IWASE T, Cohen EN, Gao H, Alexander A, et al Maintenance pembrolizumab therapy in patients with metastatic HER2-negative
breast cancer with prior response to chemotherapy.
Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-2947. PubMedAbstract available
MOYER CL, Lanier A, Qian J, Coleman D, et al IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and
Synergizes with Anti-HER2 Therapy.
Clin Cancer Res. 2024 Apr 5. doi: 10.1158/1078-0432.CCR-23-3839. PubMedAbstract available
HAN YJ, Liu S, Hardeman A, Rajagopal PS, et al The VEGF-Hypoxia Signature is Upregulated in Basal like Breast Tumors from Women
of African Ancestry and Associated with Poor Outcomes in Breast Cancer.
Clin Cancer Res. 2024 Apr 2. doi: 10.1158/1078-0432.CCR-23-1526. PubMedAbstract available
CONNOLLY RM, Wang V, Hyman DM, Grivas P, et al Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal
HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131)
Subprotocol J.
Clin Cancer Res. 2024;30:1273-1280. PubMedAbstract available
March 2024
MAGBANUA MJM, Ahmed Z, Sayaman RW, Brown Swigart L, et al Cell-free DNA concentration as a biomarker of response and recurrence in
HER2-negative breast cancer receiving neoadjuvant chemotherapy.
Clin Cancer Res. 2024 Mar 12. doi: 10.1158/1078-0432.CCR-23-2928. PubMedAbstract available
MARTIN M, Yoder R, Salgado R, Del Monte-Millan M, et al Tumor-infiltrating lymphocytes refine outcomes in triple-negative breast cancer
treated with anthracycline-free neoadjuvant chemotherapy.
Clin Cancer Res. 2024 Mar 11. doi: 10.1158/1078-0432.CCR-24-0106. PubMedAbstract available